PL2257304T3 - Kompozycje farmaceutyczne o przedłużonym uwalnianiu zawierające poloksamer - Google Patents

Kompozycje farmaceutyczne o przedłużonym uwalnianiu zawierające poloksamer

Info

Publication number
PL2257304T3
PL2257304T3 PL09712268T PL09712268T PL2257304T3 PL 2257304 T3 PL2257304 T3 PL 2257304T3 PL 09712268 T PL09712268 T PL 09712268T PL 09712268 T PL09712268 T PL 09712268T PL 2257304 T3 PL2257304 T3 PL 2257304T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
sustained release
containing pharmaceutical
poloxamer containing
release poloxamer
Prior art date
Application number
PL09712268T
Other languages
English (en)
Inventor
Terrence J. Hunt
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL2257304T3 publication Critical patent/PL2257304T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/594—Mixtures of polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/95—Involves in-situ formation or cross-linking of polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09712268T 2008-02-22 2009-02-11 Kompozycje farmaceutyczne o przedłużonym uwalnianiu zawierające poloksamer PL2257304T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/036,139 US9107815B2 (en) 2008-02-22 2008-02-22 Sustained release poloxamer containing pharmaceutical compositions
PCT/US2009/033752 WO2009105369A1 (en) 2008-02-22 2009-02-11 Sustained release poloxamer containing pharmaceutical compositions
EP09712268.3A EP2257304B1 (en) 2008-02-22 2009-02-11 Sustained release poloxamer containing pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PL2257304T3 true PL2257304T3 (pl) 2020-06-15

Family

ID=40640698

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09712268T PL2257304T3 (pl) 2008-02-22 2009-02-11 Kompozycje farmaceutyczne o przedłużonym uwalnianiu zawierające poloksamer

Country Status (12)

Country Link
US (4) US9107815B2 (pl)
EP (2) EP2257304B1 (pl)
KR (1) KR101675168B1 (pl)
CN (1) CN102014951A (pl)
AU (1) AU2009215664B2 (pl)
CA (1) CA2715626C (pl)
DK (1) DK2257304T3 (pl)
ES (1) ES2759372T3 (pl)
HU (1) HUE047394T2 (pl)
PL (1) PL2257304T3 (pl)
RU (1) RU2482874C2 (pl)
WO (1) WO2009105369A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR101753242B1 (ko) 2008-12-31 2017-07-20 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
MX366344B (es) * 2009-06-25 2019-07-05 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
CA2774826A1 (en) * 2009-10-30 2011-05-05 Revance Therapeutics, Inc. Device and method for topical application of therapeutic or cosmetic compositions
JP2013514376A (ja) * 2009-12-15 2013-04-25 サンダース，アイラ 鼻および副鼻腔の疾患の治療
US8454975B1 (en) * 2010-01-11 2013-06-04 Elizabeth VanderVeer Method for enhancing skin appearance
US10471150B2 (en) * 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
US11052043B2 (en) 2011-03-28 2021-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sustained-release injectable formulation
AU2012279001A1 (en) 2011-07-05 2014-01-23 The Research Foundation For The State University Of New York Compositions and methods for spinal disc repair and other surgical and non-surgical indications
AU2015271940B2 (en) * 2011-07-05 2018-02-08 The Research Foundation For The State University Of New York Compositions and methods for spinal disc repair and other surgical and non-surgical indications
EP2836200B1 (en) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3137053B1 (en) * 2014-04-30 2020-06-17 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2016007537A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
RU2641570C2 (ru) * 2015-01-21 2018-01-18 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, включающий нифедипин и лидокаина гидрохлорид (варианты), применение геля, включающего нифедипин и лидокаина гидрохлорид (варианты), способ приготовления геля, включающего нифедипин и лидокаина гидрохлорид, с использованием нанотехнологии
WO2016118040A1 (ru) * 2015-01-21 2016-07-28 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий
CA2974450C (en) * 2015-02-03 2024-01-09 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
ITUB20155342A1 (it) * 2015-11-06 2017-05-06 Emenem Srl Composizione di soluzioni-gel reversibili termosensibili mucoadesive a base di collagene e sali di acido ialuronico
KR102423739B1 (ko) * 2016-05-27 2022-07-21 입센 바이오팜 리미티드 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형
ES2917248T3 (es) 2016-08-26 2022-07-07 Sk Joint Ventures Ii Llc Formulaciones de polímeros biodegradables para aumentar la eficacia de la toxina botulínica
CN109803673A (zh) 2016-09-13 2019-05-24 阿勒根公司 非蛋白质梭菌毒素组合物
US20210162026A1 (en) 2017-08-28 2021-06-03 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP3470054B1 (en) * 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
MX2020006424A (es) 2017-12-20 2021-01-08 Allergan Inc Polipéptidos de dominio de unión a células de toxina botulínica y métodos de uso para el rejuvenecimiento de la piel.
WO2019123332A1 (en) * 2017-12-20 2019-06-27 Alpha Strumenti S.R.L. Pharmaceutical preparation comprising a topically released active ingredient and a heat-sensitive carrier, method of obtaining same, and use of same in the treatment of skin or mucosal infections
US10607931B2 (en) 2018-07-03 2020-03-31 Texas Instruments Incorporated Semiconductor device with electroplated die attach
JP2021536485A (ja) 2018-09-06 2021-12-27 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド 注射可能な徐放性の抗生物質製剤
CN112888454A (zh) * 2018-09-13 2021-06-01 阿勒根公司 梭菌毒素-透明质酸组合物
WO2020243844A1 (en) * 2019-06-06 2020-12-10 Hexo Operations Inc. Thermogelling cannabinoid composition and method of manufacture and use thereof
US20230000761A1 (en) * 2019-12-13 2023-01-05 Francesco BARBAGALLO Botulinum toxin formulations and methods for intranasal delivery thereof for the treatment of allergic rhinitis
KR102626199B1 (ko) * 2021-07-01 2024-01-16 순천대학교 산학협력단 온도감응성 겔을 이용한 고체분산체의 조성 및 이의 제조방법

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
JP3756512B2 (ja) * 1992-09-21 2006-03-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 徐放性タンパク質製剤
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US5516703A (en) * 1993-08-20 1996-05-14 The University Of Utah Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
EP0773788B1 (en) * 1995-06-06 2003-05-07 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US6063405A (en) * 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
RU2123837C1 (ru) * 1998-05-27 1998-12-27 Бритун Юлия Анатольевна Способ устранения морщин
US6316011B1 (en) * 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
WO2000069942A1 (en) * 1999-05-19 2000-11-23 University Of Utah Research Foundation Stabilization and acoustic activation of polymeric micelles for drug delivery
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2001058472A2 (en) 2000-02-08 2001-08-16 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
BR0108959A (pt) * 2000-03-03 2003-10-14 Valentis Inc Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
EP1443907A1 (en) * 2001-11-12 2004-08-11 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP1594523B1 (en) 2002-12-20 2009-03-25 Botulinum Toxin Research Associates, Inc. Pharmaceutical compositions comprising botulinum toxin and human serum albumin
CN1446833A (zh) * 2003-02-08 2003-10-08 复旦大学 一种温敏性可降解微凝胶及其制备方法
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
SE0300877D0 (sv) * 2003-03-26 2003-03-26 Sca Hygiene Prod Ab Absorbent article comprising an absorbent structure
EP1624859A4 (en) * 2003-05-06 2010-06-23 Bpsi Holdings Inc METHOD FOR PRODUCING THERMOFORMED COMPOSITIONS WITH ACRYLIC POLYMER BINDERS, PHARMACEUTICAL DOSAGE FORMS, AND METHOD FOR THE PRODUCTION THEREOF
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
NL1023720C2 (nl) * 2003-06-23 2004-12-28 Univ Eindhoven Tech Werkwijze voor het wijzigen van de transporteigenschappen van een materiaal, werkwijze voor het vrijmaken van een werkstof uit een implantaat, evenals implantaat met werkstof.
KR20060037320A (ko) * 2003-07-02 2006-05-03 알자 코포레이션 미세돌출부 어레이 면역화 패치 및 방법
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
EA011652B1 (ru) 2004-07-26 2009-04-28 Мерц Фарма Гмбх Унд Ко. Кгаа Терапевтические композиции с нейротоксином ботулина
BRPI0515191A (pt) * 2004-08-13 2008-07-08 Angiotech Internac Ag composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico
US20060078616A1 (en) * 2004-08-30 2006-04-13 Georgewill Dawaye A Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
US20070237740A1 (en) * 2004-09-27 2007-10-11 Vical, Inc. Formulations and Methods for Treatment of Inflammatory Diseases
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
US20060127429A1 (en) * 2004-12-13 2006-06-15 Mccartt Mary D Topical numbing composition for laser therapy
EP1861112A4 (en) * 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
DE102005011544A1 (de) * 2005-03-10 2006-09-14 Gkss-Forschungszentrum Geesthacht Gmbh Verfahren zur Herstellung einer Polymermembran sowie Polymermembran
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PL3295955T3 (pl) * 2005-12-01 2021-10-25 University Of Massachusetts Lowell Nanoemulsje botulinowe
DK1973529T3 (da) * 2006-01-05 2011-09-12 Veloxis Pharmaceuticals As Fyldbar tablet, som er i stand til at falde hen
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
NZ572207A (en) * 2006-03-24 2012-02-24 Auxilium Int Holdings Inc Stabilized compositions containing alkaline labile drugs
US20070253960A1 (en) * 2006-04-28 2007-11-01 Josee Roy Pharmaceutical removal of vascular extensions from a degenerating disc
US20080097229A1 (en) * 2006-08-29 2008-04-24 Josee Roy Hygroscopic treatment for degenerating discs
JP2010528981A (ja) * 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
KR101483715B1 (ko) * 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20090258924A1 (en) * 2008-04-15 2009-10-15 Allergan, Inc. METHODS, COMPOSITIONS AND DRUG DELIVERY SYSTEMS FOR INTRAOCULAR DELIVERY OF siRNA MOLECULES
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
US20120156244A1 (en) * 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
WO2010090677A1 (en) * 2008-12-10 2010-08-12 Allergan, Inc. Clostridial toxin pharmaceutical compositions
KR101233850B1 (ko) * 2009-06-05 2013-02-15 서울대학교산학협력단 복합체, 이를 이용한 다층, 및 상기 다층이 코팅된 디바이스
CA2774826A1 (en) * 2009-10-30 2011-05-05 Revance Therapeutics, Inc. Device and method for topical application of therapeutic or cosmetic compositions
CN102639097A (zh) * 2011-03-21 2012-08-15 博任达生化科技（上海）有限公司 逆向温敏可逆水凝胶组合物
US8816591B2 (en) 2012-05-26 2014-08-26 Vastview Technology Inc. Methods and apparatus for segmenting and driving LED-based lighting units
CN104884064A (zh) * 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
WO2016094617A1 (en) * 2014-12-11 2016-06-16 Phosphorex, Inc. Aqueous topical drug formulation with controlled release and increased stability

Also Published As

Publication number Publication date
DK2257304T3 (da) 2019-12-02
RU2010138700A (ru) 2012-03-27
RU2482874C2 (ru) 2013-05-27
CA2715626A1 (en) 2009-08-27
US20150352226A1 (en) 2015-12-10
AU2009215664A1 (en) 2009-08-27
CA2715626C (en) 2016-10-11
US9107815B2 (en) 2015-08-18
EP2257304B1 (en) 2019-09-04
AU2009215664B2 (en) 2014-07-03
US9278140B2 (en) 2016-03-08
KR20100135237A (ko) 2010-12-24
ES2759372T3 (es) 2020-05-08
US20180271959A1 (en) 2018-09-27
KR101675168B1 (ko) 2016-11-10
CN102014951A (zh) 2011-04-13
WO2009105369A1 (en) 2009-08-27
HUE047394T2 (hu) 2020-04-28
EP2257304A1 (en) 2010-12-08
US9981022B2 (en) 2018-05-29
US20090214685A1 (en) 2009-08-27
US20160175410A1 (en) 2016-06-23
EP3632470A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
HUE047394T2 (hu) Nyújtott hatóanyagleadású, poloxamert tartalmazó gyógyászati készítmények
HK1216232A1 (zh) 控釋藥物組合物
HK1164059A1 (en) Compositions for drug administration
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2323623T3 (pl) Kompozycje farmaceutyczne
ZA201100635B (en) Sustained release pharmaceutical compositions comprising quetiapine
ZA201102715B (en) Solid pharmaceutical composition
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
EP2268278A4 (en) PHARMACEUTICAL COMPOSITION
IL208788A (en) Pharmacy-based formulation
ZA201100871B (en) Solid pharmaceutical composition
IL207734A0 (en) Pharmaceutical composition
GB2464200B (en) Pharmaceutical composition
IL206487A0 (en) Pharmaceutical compositions
GB0817969D0 (en) Pharmaceutical composition
HK1182939A1 (en) Stable pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
GB0810217D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations
ZA201001127B (en) Pharmaceutical formulation for extended release
IL178378A0 (en) Extended release pharmaceutical compositions
HU0700172D0 (en) Sustained release pharmaceutical preparation
GB0802024D0 (en) Pharmaceutical compositions